Background
==========

Tumor development, progression, and prognosis remain at the front position of medical research. Two hypotheses of the origin of cancer have existed for many decades. One hypothesis postulates that adult stem or precursor cell is the cell of origin for cancer, whereas the other declares a somatic cell can be mutated and then be dedifferentiated or be reprogrammed to regain properties associated with both cancer cells and stem cells \[[@B1]-[@B3]\]. The discovery of a subpopulation of tumor stem cells (TSCs) in leukemia and solid cancers has strengthened the stem cell hypothesis \[[@B4]\]. Glioblastomas also possess characters and gene expression patterns of local neural stem cells (NSCs) \[[@B5]\], and artificially introducing cancer-associated mutations into stem or lineage-restricted precursor cells can indeed turn them into cancer initiating cells and all mice received mutations developed medulloblastomas \[[@B6],[@B7]\]. Another example that the adult stem cell represents the cell of origin of cancer has recently been made in chronic myeloid leukemia (CML): by restricting BCR-ABLp210 expression to mouse Sca1(+) hematopoietic stem cells, it is sufficient to induce CML formation that recapitulates the human disease \[[@B8]\]. These evidences support the idea that mutations of stem cells may initiate the carcinogenic process of certain, although not necessary all, tumors.

On the other hand, the importance of somatic or tumor cell mutation and dedifferentiation has not been excluded completely. It has been recognized that during malignant transformation, cancer cells acquire genetic mutations that override the normal mechanisms controlling cellular proliferation. Human tumor cells can be created from healthy somatic cells with defined genetic elements \[[@B9]\]. Even though cancers were originated from mutated stem cells, newly acquired mutations in tumors still contribute in cell malignancy and therapy resistance. It has been recognized that cancer cells acquire characters reminiscent of those of normal stem cells. Clinically cancer cells with poor differentiated pathological grading usually have worse therapy response than those with well differentiated morphology. The degree of embryonic gene re-expression correlates with pivotal tumor features and patient prognosis \[[@B10],[@B11]\]. It is known that colon cancers adopt a broad program encompassing embryonic colon development \[[@B12]\]. In poorly differentiated breast cancer, gliomas and bladder carcinoma, an embryonic stem cell (ESC)-like gene expression signature is exhibited and the degree of ESC program recapitulation correlates with tumor stages and patient survival \[[@B13]\]. Recent studies demonstrated that Snail, a potent oncogene which can induce epithelial-mesenchymal transition (EMT), contributes to the acquisition of stem cell traits in breast cancer cells \[[@B14],[@B15]\]. Pre-existing cancerous lesions may become more malignant by the accumulation of new oncogenic mutations (such as Snail) that can induce cell dedifferentiation. Identifying genes shared between transformed cells, especially the more malignant ones, and stem cells will help to unmask the pathogenesis of tumors, as well as provide us with novel therapeutic targets and prognosis biomarkers.

Endometrial carcinoma of the female genital tract can be divided into two forms: endometrial endometrioid carcinoma (EEC; Type I) which account for 70-80% of cases and are estrogen-related; whereas the Type II tumors (papillary serous or clear cell tumors) account for 20% of cases unrelated to estrogen stimulation \[[@B16]\]. Clinically endometrial carcinoma is classified into 4 FIGO stages by the degree of invasion and metastasis: stage I tumors are limit to the uterine body and stage II tumors extend to the uterine cervix. Both stages are considered as less invasive, although stage IIB cases are characterized by a less favorable prognosis. In contrast, tumors of stages III-IV are invasive: for stage III there is regional tumor spread and for stage IV there is bulky pelvic disease or distant spread \[[@B17]\]. Approximately 72% of endometrial carcinomas are stage I, 12% are stage II, 13% are stage III, and 3% are stage IV \[[@B17]\]. The survival rate is also low in patients with higher stages of tumors: 80-90% in stage I, 70-80% in stage II, 40-60% in stage III, and 20% in stage IV \[[@B17]\]. Identifying genes abundant in late EECs can not only unmask the mechanisms of tumor malignancy but also provide us with novel therapeutic targets. Recently Lgr5- or CD133-positive crypt stem cells of the intestinal track were identified and these cells were proven to be one of the original cells of intestinal cancer \[[@B18],[@B19]\]. OLFM4 is also a new, robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells \[[@B20]\]. Disruption of beta-catenin in cells positive for CD133 resulted in a gross disruption of crypt architecture and a disproportionate expansion of CD133(+) cells at the crypt base \[[@B19]\]. It is unclear, however, whether genes high expressed in epithelial stem cells (EpiSCs) also contribute in tumor invasiveness, malignancy and therapy resistance. A broad description of stem cell traits reminiscent in EECs is therefore crucial.

In this study we dealt with the molecular bases of endometrial cancer and assessed the expression of epithelial precursor genes in advanced EEC. To examine the shared genes between EpiSC and late EECs, we first need to unmask the gene compositions in different stages of EECs. For this purpose we applied gene expression microarray and machine learning algorithms to filtrate genes differentially expressed in early (stages I-II) and late (stages III-IV) EECs. After obtaining genes unique in EECs of different stages, we then related transcriptional programs in EpiSCs and late EECs. This approach helped to discover a total of 217 probe sets differentiating EECs of different stages, and, moreover, showed late EECs possess a clear EpiSC gene expression pattern, partly explaining why these tumors are more malignant and fatal.

Results
=======

Molecular signatures of early and late stage EECs
-------------------------------------------------

To identify epithelial stem cell genes in late EECs, we first delineated early (FIGO stages I and II) and late (FIGO stages III and IV) EECs at the genomics level. We explored genes differentially expressed between early and late EEC tissues using the Affymetrix U133 Plus 2.0 array. The demographics of patients in the training and testing cohorts are in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively. Tumor samples were compared to each other to minimize stromal and myometrial contamination as well as female-specific genes. A multidimensional scaling (MDS) plot using the whole transcriptome showed that the mRNA profiles of normal and cancerous tissues are different (Figure [1A](#F1){ref-type="fig"}). We then searched for genes distinguishing early and late EECs according to a statistical pipeline we used \[[@B21],[@B22]\]. A total of 678 probe sets could differentiate early and late stage samples, as well as discriminate 23 normal endometrium and 33 tumor tissues (Figure [1B](#F1){ref-type="fig"}; the positive false discovery rate (pFDR) cutoff q values are shown).

###### 

Characteristics of 34 EEC patients used in the training cohort.

  GSE No.                                       TNM              FIGO stage   Histology        FIGO grade   Patient Age   Ethnic Background
  --------------------------------------------- ---------------- ------------ ---------------- ------------ ------------- -------------------
  ***(Isolation site: Endometrium)***                                                                                     
  GSM117600                                     T1aN0M0          1A           Adenocarcinoma   1            60-70         Asian
  GSM152644                                     T1bN0M0          1B           Endometrioid     2            60-70         Caucasian
  GSM152660                                     T1bN0M0          1B           Endometrioid     2            40-50         Caucasian
  GSM137960                                     T1bN0M0          1B           Endometrioid     2            60-70         Caucasian
  GSM137968                                     T1bN0M0          1B           Endometrioid     2            60-70         Caucasian
  GSM137980                                     T1bN0M0          1B           Endometrioid     3            40-50         Caucasian
  GSM117586                                     T1bN0M0          1B           Endometrioid     2            50-60         African-American
  GSM117643                                     T1bN0M0          1B           Endometrioid     1            70-80         Caucasian
  GSM117667                                     T1bN0M0          1B           Endometrioid     2            60-70         Caucasian
  GSM117703                                     T1bN0M0          1B           Endometrioid     2            50-60         Caucasian
  GSM117704                                     T1bN0M0          1B           Endometrioid     2            50-60         Caucasian
  GSM117722                                     T1bN0M0          1B           Endometrioid     2            70-80         Caucasian
  GSM117724                                     T1bN0M0          1B           Endometrioid     2            60-70         Caucasian
  GSM117739                                     T1bN0M0          1B           Endometrioid     3            60-70         Caucasian
  GSM89034                                      T1bN0                         Endometrioid     2            40-50         Caucasian
  GSM89089                                      T1bN0M0          1B           Endometrioid     1            70-80         Caucasian
  GSM76499                                      T1bN0M0          1B           Endometrioid     2            70-80         Caucasian
  GSM76638                                      T1bN0M0          1B           Endometrioid     2            60-70         Caucasian
  GSM117697                                     T1cN0M0          1C           Endometrioid     3            60-70         Caucasian
  GSM89076                                      T1cN0M0          1C           Endometrioid     3            70-80         African Indian
  GSM76507                                      T1cN0M0          1C           Endometrioid     2            60-70         Caucasian
  GSM137955                                     T2aN0M0          2A           Endometrioid     2            60-70         African-American
  GSM102425                                     T2bN0M0          2B           Endometrioid     2            50-60         Caucasian
  GSM102444                                     T2bN0M0          2B           Endometrioid     1            60-70         Caucasian
  GSM46912                                      T2bN0M0          2B           Endometrioid     1            60-70         Caucasian
                                                                                                                          
  GSM117708                                     T3aN0M0          3A           Endometrioid     3            70-80         Caucasian
  GSM117712                                     T3aN0M0          3A           Endometrioid     2            60-70         Caucasian
  GSM38067                                      T3aN0M0          3A           Endometrioid     3            60-70         Caucasian
  GSM38084                                      T4NXM0           4A           Endometrioid     3            60-70         Caucasian
  GSM89087                                      T3aNXM1 (\*)     4B           Endometrioid     3            80-90         Caucasian
  GSM46867                                      T3aN1M1 (\*\*)   4B           Endometrioid     3            60-70         Caucasian
  ***(Isolation site: outside endometrium)***                                                                             
  GSM89079                                      T3aNXM1(\$)      4B           Endometrioid     3            40-50         Caucasian
  GSM203686                                     T3aN0M0 (\$)     3A           Endometrioid     2            60-70         Caucasian
  GSM46932                                      TXNXM1(@)        4B           Endometrioid     2            50-60         Caucasian

Endometrioid: Endometrioid carcinoma

\*: Hepatic metastasis

\*\*: Lymph node metastasis

\$: Isolated from ovary

@: Isolated from abdominal wall fascia

###### 

Characteristics of another 15 early EEC patients used in the testing set.

  GSE No.     TNM       FIGO stage   Histology            FIGO grade   Patient Age   Ethnic Background
  ----------- --------- ------------ -------------------- ------------ ------------- -------------------
  GSM88952    T1aN0M0   1A           Endometrioid         2            50-60         Caucasian
  GSM76487    T1bN0M0   1B           Endometrioid         1            30-40         Caucasian
  GSM102469   T1bN0M0   1B           Endometrioid         1            60-70         Caucasian
  GSM117579   T1bN0MX   1B           Endometrioid         1            80-90         African-American
  GSM117589   T1bN0MX   1B           Endometrioid         1            80-90         Caucasian
  GSM117767   T1bN0MX   1B           Endometrioid         2            60-70         Caucasian
  GSM137961   T1bN0MX   1B           Endometrioid         2            60-70         Caucasian
  GSM117590   T1cN0MX   1C           Endometrioid         2            70-80         Caucasian
  GSM117729   T2aN0M0   2A           Endometrioid         1            50-60         Caucasian
  GSM53176    T2aN0MX   2A           Endometrioid         1            60-70         Caucasian
  GSM117582   T2aN0MX   2A           Endometrioid         2            40-50         Caucasian
  GSM88966    T2aN1M0   2A           Endometrioid         2            80-90         Caucasian
  GSM53174    T2bN0MX   2B           Adenosarcoma         2            60-70         Caucasian
  GSM76525    T1aN0M0   1A           Endometrioid (Mix)   3            80-90         Caucasian
  GSM76632    T1bN0M0   1B           Adenocarcinoma       2            50-60         Caucasian

Mix: Mixed endometrioid and serous adenocarcinoma

![**Identification of genes in different EECs**. **(A)**A multidimensional scaling (MDS) plot drawn by all probe sets (\~54600 ones) on the chip. Normal endometrium (Normal) and EECs of all 4 stages are included. Each spot represents an array. (**B**) A Venn diagram summarizing genes differentially expressed between normal and tumor tissues or between early (Stages 1 & 2) and late (Stages 3 & 4) EEC samples in the training cohort. (**C**) Narrowing down the existing gene signature using a machine learning strategy. When probe sets were ranked by signal-to-noise ratios (weights), the top 217 features was the largest panel to give the lowest error rate (i.e., a best classification effect; *upper panel*). (**D**) The discrimination ability of the 217-probeset signature. A prediction strength plot \[25\] shows the prediction strengths of the identified 217 probe sets in discriminating early from late EECs in the training cohort. Samples 1B and 2B denote 2 early EECs (Stages 1B and 2B, respectively) which express late EEC gene signatures. (**E**) A MDS plots using the above 217 probe sets. 2 misgrouped early EECs are indicated. (**F**) Signature evaluation by an independent testing data set. One Stage 1B case, which expresses late EEC gene signatures, is grouped into the late EEC area (separated by a red line).](1471-2164-10-613-1){#F1}

The discrimination ability of these 678 probe sets were evaluated by a supervised machine learning strategy, which combines the weighted voting algorithm and leave-one-out cross validation (LOOCV) \[[@B23]-[@B25]\]. An error rate of 12.1% (2 out of 24 early cancers and 2 out of 9 late samples; P \< 0.001 by permutation test) was found (Figure [1C](#F1){ref-type="fig"} and Additional file [1](#S1){ref-type="supplementary-material"}). However, we found the top 217 features (ranked by the weighted value of each probe set \[[@B25]\]) is the largest panel to have better discrimination ability than that of the 678-probeset signature (error rate 6.1% vs. 12.1%; Figure [1C](#F1){ref-type="fig"}, upper panel): 2 out of 24 early EEC tissues are classified into the late group while all 9 late ones are correct (Figure [1D](#F1){ref-type="fig"}). MDS analysis supports the superior classification power of these 217 probe sets: only 2 early samples express late EECs gene signatures and are grouped together with the late cases (Figure [1E](#F1){ref-type="fig"}). When applying these 217 probe sets on another independent testing data set containing 15 early EEC cases, 1 out of 15 early tissues (error rate 6.7%; P \< 0.001 by permutation test) is misgrouped (Figure [1F](#F1){ref-type="fig"}).

In-depth exploration of EEC-related genes
-----------------------------------------

To have a better idea how the filtrated genes distribute in early and late EECs, a gene expression heat map for those 217 probe sets was drawn (Figure [2](#F2){ref-type="fig"}). This heat map showed the unique gene expression patterns between early or late EEC tumor tissues. Consistent with the classification data obtained by prediction strength (PS) analysis in Figure [1D](#F1){ref-type="fig"}, hierarchical clustering showed that only 2 early cases in the training data set are misclassified (indicated by arrows; Figure [2](#F2){ref-type="fig"}).

![**Molecular fingerprint of EEC subtypes**. A heat map shows the 217 probes sets differentiating early and late EECs in the training data set, as well as discriminating normal endometrium and tumor tissues. Columns represent tumor samples; rows represent probe sets. In red, increased; in blue, decreased. Arrows indicates two early EECs which express a late EEC gene signature (black, Stage 1B; red, Stage 2B).](1471-2164-10-613-2){#F2}

Those 217 probe sets correspond to 177 known genes (with gene symbols) and 29 cDNAs, which have no gene symbols been assigned yet (all in Additional file [2](#S2){ref-type="supplementary-material"}). Among them 58 genes/cDNAs are predominantly up in early ECCs while 25 being down (Figure [2](#F2){ref-type="fig"}). In contrast, 48 genes/cDNAs are particularly high in late EECs while another 75 being low (Figure [2](#F2){ref-type="fig"}). The details of known genes (especially those with known function) are in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"} respectively. Many of these genes, such as CD163 \[[@B26]\], MSR1 (CD204) \[[@B27]\], ERBB2 oncogene (also known as HER-2/neu) \[[@B28],[@B29]\], CSTA (stefin A) \[[@B30]\] and CCR1 \[[@B31]\], have been associated with tumor malignancy and poor patient outcomes in EEC or other cancers (Table [3](#T3){ref-type="table"}, bold). CD163 and MSR1 (macrophage scavenger receptor 1; CD204) are markers for M2 macrophages, whose infiltration in tumor lesions is correlated with the histological grade of the gliomas \[[@B27]\] (Table [3](#T3){ref-type="table"}, bold). These consistent findings support the reliability of our gene lists. We also validated our array data by performing immunohistochemical staining on Taiwanese EEC cases. ERBB2 was indeed more abundant in stages III and IV EEC tissues (Figure [3](#F3){ref-type="fig"}).

![**ERBB2 protein expression in early and late EECs**. (**A**) Representative immunohistochemical (IHC) staining of ERBB2 protein in primary EEC tissues. Staining results were graded as 0+: undetectable staining in \<10% of the tumor cells; 2+: weak to moderate complete membrane staining (indicated by an arrow) in \<10% of the tumor cells; 3+: strong complete membrane staining observed in \<10% of the tumor cells. EEC cases were categorized as ERBB2-negative (scores 0 and 1+) or positive (scores 2+ and 3+). (**B**) A histogram summarizing the IHC results on 36 primary EEC tissues stained for ERBB2. A chi square test P value is shown. Case numbers and percentages are also indicated.](1471-2164-10-613-3){#F3}

###### 

Up-regulated known genes in late stage EECs.

  Probe Set ID    UniGene ID   Gene Title                                        Gene Symbol        Chromosomal Location
  --------------- ------------ ------------------------------------------------- ------------------ ----------------------
  213532_at       Hs.404914    ADAM metallopeptidase domain 17                   ADAM17             chr2p25
  223660_at       Hs.281342    adenosine A3 receptor                             ADORA3             chr1p13.2
  200966_x\_at    Hs.513490    aldolase A, fructose-bisphosphate                 ALDOA              chr16q22-q24
  205568_at       Hs.104624    aquaporin 9                                       AQP9               chr15q22.1-22.2
  224376_s\_at    Hs.584985    chromosome 20 open reading frame 24               C20orf24           chr20q11.23
  224972_at       Hs.472564    chromosome 20 open reading frame 52               C20orf52           chr20q11.22
  200625_s\_at    Hs.370581    CAP, adenylate cyclase-associated protein 1       CAP1               chr1p34.2
  201850_at       Hs.516155    capping protein (actin filament), gelsolin-like   CAPG               chr2p11.2
  205098_at       Hs.301921    chemokine (C-C motif) receptor 1                  **CCR1**           chr3p21
  203645_s\_at    Hs.504641    CD163 molecule                                    **CD163**          chr12p13.3
  209396_s\_at    Hs.382202    chitinase 3-like 1 (cartilage glycoprotein-39)    CHI3L1             chr1q32.1
  204971_at       Hs.518198    cystatin A (stefin A)                             **CSTA**           chr3q21
  202190_at       Hs.172865    cleavage stimulation factor, subunit 1, 50kDa     CSTF1              chr20q13.31
  1554863_s\_at   Hs.473133    docking protein 5                                 DOK5               chr20q13.2
  224336_s\_at    Hs.536535    dual specificity phosphatase 16                   DUSP16             chr12p13
  218282_at       Hs.632276    ER degradation enhancer mannosidase a-like 2      EDEM2              chr20q11.22
  216836_s\_at    Hs.446352    v-erb-b2 erythroblastic leukemia viral oncogene   **ERBB2 (HER2)**   chr17q11.2-q12
  203561_at       Hs.78864     IgG Fc fragment, IIa, receptor (CD32)             FCGR2A             chr1q23
  210889_s\_at    Hs.352642    IgG Fc fragment, IIb, receptor (CD32)             FCGR2B             chr1q23
  210992_x\_at    Hs.78864     IgG Fc fragment, IIc, receptor (CD32)             FCGR2C             chr1q23.3
  204007_at       Hs.176663    IgG Fc fragment, IIIb, receptor (CD16b)           FCGR3B             chr1q23
  217782_s\_at    Hs.268530    G protein pathway suppressor 1                    GPS1               chr17q25.3
  212355_at       Hs.558466    KIAA0323                                          KIAA0323           chr14q12
  203364_s\_at    Hs.410092    KIAA0652                                          KIAA0652           chr11p11.2
  230252_at       Hs.155538    lysophosphatidic acid receptor 5                  LPAR5              chr12p13.31
  228360_at       Hs.357567    hypothetical protein LOC130576                    LOC130576          chr2q23.2
  226710_at       Hs.105685    similar to RIKEN cDNA C030006K11 gene             MGC70857           chr8q24
  224324_at       Hs.131072    maestro                                           MRO                chr18q21
  226241_s\_at    Hs.355935    mitochondrial ribosomal protein L52               MRPL52             chr14q11.2
  214770_at       Hs.632045    macrophage scavenger receptor 1                   **MSR1 (CD204)**   chr8p22
  205460_at       Hs.156832    neuronal PAS domain protein 2                     NPAS2              chr2q11.2
  209222_s\_at    Hs.473254    oxysterol binding protein-like 2                  OSBPL2             chr20q13.3
  210907_s\_at    Hs.478150    programmed cell death 10                          PDCD10             chr3q26.1
  238693_at       Hs.529592    Polyhomeotic like 3 (Drosophila)                  PHC3               chr3q26.2
  203691_at       Hs.112341    peptidase inhibitor 3, skin-derived (SKALP)       PI3                chr20q12-q13
  226577_at       Hs.593811    Presenilin 1 (Alzheimer diseas 3)                 PSEN1              chr14q24.3
  217811_at       Hs.369052    selenoprotein T                                   SELT               chr3q25.1
  222523_at       Hs.401388    SUMO1/sentrin/SMT3 specific peptidase 2           SENP2              chr3q27.2
  227518_at       Hs.585896    solute carrier family 35, member E1               SLC35E1            chr19p13.11
  1552671_a\_at   Hs.496057    solute carrier family 9 (Na/H exchanger), 7       SLC9A7             chrXp11.3-11.23
  222410_s\_at    Hs.583855    sorting nexin 6                                   SNX6               chr14q13.2
  203114_at       Hs.25723     Sjogren\'s syndrome/scleroderma autoantigen 1     SSSCA1             chr11q13.1
  223478_at       Hs.530373    translocase of inner mitochondrial 8 homolog B    TIMM8B             chr11q23.1-q23.2
  212769_at       Hs.287362    transducin-like enhancer of split 3               TLE3               chr15q22
  204787_at       Hs.8904      V-set and immunoglobulin domain containing 4      VSIG4              chrXq12-q13.3
  221247_s\_at    Hs.900069    Williams-Beuren syndrome region 16                WBSCR16            chr7q11.23
  202939_at       Hs.591501    zinc metallopeptidase (STE24 homolog, yeast)      ZMPSTE24           chr1p34
  219050_s\_at    Hs.121025    zinc finger, HIT type 2                           ZNHIT2             chr11q13

###### 

Down-regulated known genes in late stage EECs.

  Probe Set ID    UniGene ID   Gene Title                                          Gene Symbol   Chromosomal Location
  --------------- ------------ --------------------------------------------------- ------------- ----------------------
  211224_s\_at    Hs.158316    ATP-binding cassette, sub-family B, 11              ABCB11        chr2q24
  232948_at       Hs.444414    AF4/FMR2 family, member 3                           AFF3          chr2q11.2-q12
  207133_x\_at    Hs.99691     alpha-kinase 1                                      ALPK1         chr4q25
  1562271_x\_at   Hs.508738    Rho guanine nucleotide exchange factor 7            ARHGEF7       chr13q34
  243899_at       Hs.579108    ADP-ribosylation factor-like 17 pseudogene 1        ARL17P1       chr17q21.32
  211076_x\_at    Hs.143766    Atrophin 1                                          ATN1          chr12p13.31
  214256_at       Hs.128041    ATPase, Class V, type 10A                           ATP10A        chr15q11.2
  237716_at       Hs.434253    Chromosome 9 open reading frame 3                   C9orf3        chr9q22.32
  233844_at       Hs.522805    CD99 molecule-like 2                                CD99L2        chrXq28
  243640_x\_at    Hs.127411    CDC14 cell division cycle 14 homolog A              CDC14A        chr1p21
  233630_at       Hs.472027    CDP-diacylglycerol synthase 2                       CDS2          chr20p13
  210701_at       Hs.461361    craniofacial development protein 1                  CFDP1         chr16q22.2-q22.3
  238863_x\_at    Hs.130849    Component of oligomeric golgi complex 8             COG8          chr16q22.1
  215377_at       Hs.501345    C-terminal binding protein 2                        CTBP2         chr10q26.13
  1561616_a\_at   Hs.591570    dynein, axonemal, heavy polypeptide 6               DNAH6         chr2p11.2
  1560042_at      Hs.591566    family with sequence similarity 82, A               FAM82A        chr2p22.2
  243588_at       Hs.403917    FERM, RhoGEF & pleckstrin domain protein 1          FARP1         chr13q32.2
  243876_at       Hs.189409    Formin binding protein 1                            FNBP1         chr9q34
  1560094_at      Hs.155090    Guanine nucleotide binding protein, β 5             GNB5          chr15q21.2
  210855_at       Hs.467733    GREB1 protein                                       GREB1         chr2p25.1
  1557289_s\_at   Hs.334930    GTF2I repeat domain containing 2                    GTF2IRD2      chr7q11.23
  232889_at       Hs.620129    glucuronidase, beta pseudogene 1                    GUSBP1        chr5q13.2
  1555685_at      Hs.463511    Hexose-6-phosphate dehydrogenase                    H6PD          chr1p36
  240482_at       Hs.519632    Histone deacetylase 3                               HDAC3         chr5q31
  1559600_at      Hs.632767    Hypermethylated in cancer 2                         HIC2          chr22q11.21
  1557329_at      Hs.371350    Holocarboxylase synthetase                          HLCS          chr21q22.1
  1553111_a\_at   Hs.534040    kelch repeat and BTB domain containing 6            KBTBD6        chr13q14.11
  231875_at       Hs.374201    kinesin family member 21A                           KIF21A        chr12q12
  232814_x\_at    Hs.20107     Kinesin 2                                           KNS2          chr14q32.3
  242112_at       Hs.631954    LSM11, U7 small nuclear RNA associated              LSM11         chr5q33.3
  232418_at       Hs.30824     leucine zipper transcription factor-like 1          LZTFL1        chr3p21.3
  1560033_at      Hs.167531    Methylcrotonoyl-Coenzyme A carboxylase 2            MCCC2         chr5q12-q13
  216783_at       Hs.187866    Neuroplastin                                        NPTN          chr15q22
  217802_s\_at    Hs.632458    nuclear casein kinase and CDK substrate 1           NUCKS1        chr1q32.1
  232644_x\_at    Hs.518750    OCIA domain containing 1                            OCIAD1        chr4p11
  233270_x\_at    Hs.491148    Pericentriolar material 1                           PCM1          chr8p22-p21.3
  1558695_at      Hs.188614    Pleckstrin homology domain containing, A5           PLEKHA5       chr12p12
  233458_at       Hs.460298    polymerase (RNA) III polypeptide E                  POLR3E        chr16p12.1
  1566541_at      Hs.580351    Protein kinase C, epsilon                           PRKCE         chr2p21
  235004_at       Hs.519904    RNA binding motif protein 24                        RBM24         chr6p22.3
  212044_s\_at    Hs.523463    Ribosomal protein L27a                              RPL27A        chr11p15
  215599_at       Hs.535014    SMA4                                                SMA4          chr5q13
  1556784_at      Hs.551967    Smith-Magenis syndrome region, candidate 7          SMCR7         chr17p11.2
  217704_x\_at    Hs.628886    Suppressor of zeste 12 homolog pseudogene           SUZ12P        chr17q11.2
  215279_at       Hs.499209    Supervillin                                         SVIL          chr10p11.2
  207365_x\_at    Hs.435667    thyroid hormone receptor, beta                      THRB          chr3p24.2
  215428_at       Hs.510833    Tight junction protein 1 (zona occludens 1)         TJP1          chr15q13
  225004_at       Hs.514211    transmembrane protein 101                           TMEM101       chr17q21.31
  242347_at       Hs.8752      Transmembrane protein 4                             TMEM4         chr12q15
  238079_at       Hs.576468    tropomyosin 3                                       TPM3          chr1q21.2
  237513_at       Hs.98609     trypsin X3                                          TRY1          chr7q34
  1557571_at      Hs.439381    Vacuolar protein sorting 13 homolog D               VPS13D        chr1p36.22
  235551_at       Hs.248815    WD repeat domain 4                                  WDR4          chr21q22.3
  1555259_at      Hs.444451    sterile alpha motif and leucine zipper kinase AZK   ZAK           chr2q24.2

###### 

Up-regulated biological modules in late EECs.

  Biological Process                                 \%       P-Value   Genes
  -------------------------------------------------- -------- --------- --------------------------------------------------------------------
  Regulation of catalytic activity                   12.50%   0.0053    DUSP16, **CAP1**, **ADORA3**, **ERBB2**, GPS1, **PSEN1**
  Immune system process                              16.67%   0.01694   AQP9, FCGR2A, FCGR2B, FCGR2C, FCGR3B, CCR1, ERBB2, VSIG4
  Second-messenger-mediated signalling               8.33%    0.02006   **CAP1**, **ADORA3**, ERBB2, **CCR1**
  Regulation of MAP kinase activity                  6.25%    0.02205   **DUSP16**, ERBB2, **GPS1**
  Cell surface receptor linked signal transduction   20.83%   0.02535   TLE3, CAP1, SENP2, ADORA3, ERBB2, LPAR5, CCR1, ADAM17, PSEN1, SNX6
  Membrane organization and biogenesis               8.33%    0.0314    CAP1, ZMPSTE24, MSR1, TIMM8B

###### 

Up-regulated known genes in early stage EECs.

  Probe Set ID   UniGene ID   Gene Title                                       Gene Symbol     Chromosomal Location
  -------------- ------------ ------------------------------------------------ --------------- ----------------------
  225054_x\_at   Hs.293560    Archaemetzincins-2                               AMZ2            chr17q24.2
  209870_s\_at   Hs.525718    amyloid beta (A4) precursor protein-binding A2   **APBA2**       chr15q11-q12
  1560851_at     Hs.351856    chromosome 10 open reading frame 136             C10orf136       chr10q11.21
  234457_at      Hs.512758    chromosome 6 open reading frame 12               C6orf12         chr6p21.33
  1561271_at     Hs.328147    coiled-coil domain containing 144C               CCDC144C        chr17p11.2
  211156_at      Hs.512599    cyclin-dependent kinase inhibitor 2A (p16)       **CDKN2A**      chr9p21
  220335_x\_at   Hs.268700    esterase 31                                      CES3            chr16q22.1
  204373_s\_at   Hs.557659    centrosomal protein 350kDa                       CEP350          chr1p36.13-q41
  233502_at      Hs.12723     Contactin 3 (plasmacytoma associated)            CNTN3           chr3p26
  244187_at      Hs.512181    Chromosome X open reading frame 33               CXorf33         chrXq21.1
  229738_at      Hs.577398    dynein, axonemal, heavy polypeptide 10           DNAH10          chr12q24.31
  219651_at      Hs.317659    developmental pluripotency associated 4          **DPPA4**       chr3q13.13
  1555118_at     Hs.441145    ectonucleoside tri-P diphosphohydrolase 3        ENTPD3          chr3p21.3
  206794_at      Hs.390729    v-erb-a erythroblastic leukemia viral oncogene   ERBB4           chr2q33.3-q34
  241252_at      Hs.99480     establishment of cohesion 1 homolog 2            **ESCO2**       chr8p21.1
  209631_s\_at   Hs.406094    G protein-coupled receptor 37                    **GPR37**       chr7q31
  229714_at      Hs.171001    heparan sulfate 6-O-sulfotransferase 3           HS6ST3          chr13q32.1
  213598_at      Hs.533222    Dimethyladenosine transferase                    HSA9761         chr5q11-q14
  231500_s\_at   Hs.444600    SLC7A5 pseudogene                                LAT1-3TM        chr16p11.2
  232953_at      Hs.566209    hypothetical LOC400723                           LOC400723       chr11p15.5
  239076_at      Hs.520804    Similar to cell division cycle 10 homolog        LOC441220       chr7p13
  1558579_at     Hs.587089    hypothetical protein LOC642691                   LOC642691       chr2p11.1
  222159_at      Hs.497626    Plexin A2                                        PLXNA2          chr1q32.2
  226766_at      Hs.13305     roundabout, axon guidance receptor, 2            **ROBO2**       chr3p12.3
  1569124_at     Hs.267765    similar to Leucine-rich repeat protein SHOC-2    RP11-139H14.4   chr13q14.12
  220232_at      Hs.379191    stearoyl-CoA desaturase 5                        SCD5            chr4q21.22
  214257_s\_at   Hs.534212    SEC22 vesicle trafficking protein homolog B      SEC22B          chr1q21.1
  242536_at      Hs.205816    Solute carrier family 17, member 1               SLC17A1         chr6p23-p21.3
  220551_at      Hs.242821    solute carrier family 17, member 6               SLC17A6         chr11p14.3
  1559208_at     Hs.437696    ST7 overlapping transcript 4 (non-coding RNA)    ST7OT4          chr7q31.1-7q31.2
  233251_at      Hs.21379     Spermatid perinuclear RNA binding protein        STRBP           chr9q33.3
  223751_x\_at   Hs.120551    toll-like receptor 10                            TLR10           chr4p14
  217797_at      Hs.301412    ubiquitin-fold modifier conjugating enzyme 1     UFC1            chr1q23.3
  229997_at      Hs.515130    vang-like 1 (van gogh, Drosophila)               **VANGL1**      chr1p11-p13.1
  204590_x\_at   Hs.592009    vacuolar protein sorting 33 homolog A            VPS33A          chr12q24.31
  232964_at      Hs.488157    Williams Beuren syndrome region 19               WBSCR19         chr7p13
  227621_at      Hs.446091    Wilms tumor 1 associated protein                 WTAP            chr6q25-q27
  240296_at      Hs.98322     Zinc finger, A20 domain containing 1             ZA20D1          chr1q21.2
  226208_at      Hs.593643    zinc finger, SWIM-type containing 6              ZSWIM6          chr5q12.1

###### 

Down-regulated known genes in early stage EECs.

  Probe Set ID   UniGene ID   Gene Title                                        Gene Symbol   Chromosomal Location
  -------------- ------------ ------------------------------------------------- ------------- ----------------------
  215535_s\_at   Hs.409230    1-acylglycerol-3-phosphate O-acyltransferase 1    AGPAT1        chr6p21.3
  202204_s\_at   Hs.295137    autocrine motility factor receptor                AMFR          chr16q21
  212536_at      Hs.478429    ATPase, Class VI, type 11B                        ATP11B        chr3q27
  220975_s\_at   Hs.201398    C1q and tumor necrosis factor related protein 1   C1QTNF1       chr17q25.3
  224794_s\_at   Hs.495230    cerebral endothelial cell adhesion molecule 1     CEECAM1       chr9q34.11
  1557394_at     Hs.249600    discs, large homolog-associated protein 4         DLGAP4        chr20q11.23
  211958_at      Hs.369982    insulin-like growth factor binding protein 5      IGFBP5        chr2q33-q36
  225303_at      Hs.609291    kin of IRRE like (Drosophila)                     KIRREL        chr1q21-q25
  218717_s\_at   Hs.374191    leprecan-like 1                                   LEPREL1       chr3q28
  209205_s\_at   Hs.436792    LIM domain only 4                                 LMO4          chr1p22.3
  203506_s\_at   Hs.409226    mediator of RNA polymerase II transcription 12    MED12         chrXq13
  207564_x\_at   Hs.405410    O-linked N-acetylglucosamine transferase          OGT           chrXq13
  214484_s\_at   Hs.522087    opioid receptor, sigma 1                          OPRS1         chr9p13.3
  203244_at      Hs.567327    peroxisomal biogenesis factor 5                   PEX5          chr12p13.3
  241916_at      Hs.130759    Phospholipid scramblase 1                         PLSCR1        chr3q23
  229001_at      Hs.601513    Protein phosphatase 1, regulatory 3E              PPP1R3E       chr14q11.2
  208720_s\_at   Hs.282901    RNA binding motif protein 39                      RBM39         chr20q11.22
  209148_at      Hs.388034    retinoid × receptor, beta                         RXRB          chr6p21.3
  209352_s\_at   Hs.13999     SIN3 homolog B, transcription regulator (yeast)   SIN3B         chr19p13.11
  221500_s\_at   Hs.307913    syntaxin 16                                       STX16         chr20q13.32
  220036_s\_at   Hs.272838    syntaxin 6                                        STX6          chr1q25.3
  201110_s\_at   Hs.164226    thrombospondin 1                                  THBS1         chr15q15
  221507_at      Hs.631637    transportin 2 (importin 3, karyopherin b 2b)      TNPO2         chr19p13.13
  208723_at      Hs.171501    ubiquitin specific peptidase 11                   USP11         chrXp11.23

To gain more insights into the functional consequences of differential gene expression, we performed gene set enrichment analysis for the filtrated genes. Signature probe sets were subjected into the Gene Ontology (GO) database search to find statistically over-represented functional groups within these genes. The biological processes being statistically overrepresented (P \< 0.05) in late stage-enriched genes are shown in Table [5](#T5){ref-type="table"}. These predominant processes include those pertaining to immune system process, second-messenger-mediated signaling (genes also involved in cyclic nucleotide second messenger (P = 0.0306) are bold), MAP kinase activity (genes also involved in the inactivation of MAPK activity (P = 0.0459) are bold), membrane organization and biogenesis, regulation of catalytic activity (genes also involved in the positive regulation of catalytic activity (P = 0.0182) are bold), and cell surface receptor-linked signal transduction are significantly up (Table [5](#T5){ref-type="table"}).

For genes enriched in early EECs, CDKN2A (P16) tumor suppressor was found to be reverse correlated with EEC prognosis \[[@B32]\] (Table [6](#T6){ref-type="table"}, bold). Another tumor suppressor is APBA2 (amyloid beta (A4) precursor protein-binding, family A, member 2; also known as MINT2), which is frequently methylated and silent in colorectal carcinoma and gastric carcinoma \[[@B33]\]. Hypermethylation of GPR37 is also frequently found in acute myeloid leukemia \[[@B34]\]. In terms of oncogenes, ROBO2 (roundabout, axon guidance receptor, 2), a receptor of the SLIT2 axon guidance and cell migration growth factor, is associated with poor prognosis of breast cancer \[[@B35]\]. ESCO2 (establishment of cohesion 1 homolog 2) is tightly correlated with BRCA1-dependent and various cell-type specific carcinogenesis \[[@B36]\], and DAPP4 pluripotent factor is enriched in seminomas \[[@B37]\]. VANGL1 (also known as KITENIN or STB2) acts as an executor in colon cancer cells with regard to cell motility and thereby controls cell invasion, which may contribute to promoting metastasis \[[@B38]\]. The abundant expression of known oncogenes in early EECs also suggests the early EEC cases contain high percentage of epithelial tumor cells instead of merely stromal and myometrial contaminations.

A six-gene signature distinguishing early and late EECs
-------------------------------------------------------

When evaluating the classification effect of filtrated genes, we noticed that the top 6 genes could already distinguish early and late EECs, and these 6 genes gave the same diagnostic power to that of the 217 probe sets in the training cohort (Figure [4A](#F4){ref-type="fig"}). The same two early cases (one Stage 1B and one Stage 2B) were misgrouped with the late ones (Figure [4B](#F4){ref-type="fig"}). When applying these 6 genes on the testing data set, a lowest error rate could also be achieved (Figure [4C](#F4){ref-type="fig"}, upper panel). Only 1 out of 15 early tissues (error rate 6.7%; P \< 0.001 by permutation test) was misgrouped (Figure [4C](#F4){ref-type="fig"}, lower panel). The same Stage 1B sample was misclassified when either applied only these 6 genes or the entire 217 probe sets (Figure [1F](#F1){ref-type="fig"}). Thus, these 6 genes hold clinical potentials of being diagnostic biomarkers. These 6 genes are: (1) ATP-binding cassette, B (MDR/TAP), 11 (ABCB11) (2) Archaemetzincins-2 (AMZ2) (3) amyloid beta (A4) precursor protein-binding A2 (APBA2) (4) LIM domain only 4 (LMO4) (5) Hypothetical protein LOC647065 (LOC647065) and (6) Homo sapiens mRNA, clone IMAGE:5759975 (cDNA FLJ12258 fis) (Table [8](#T8){ref-type="table"}). AMZ and APBA2 are up-regulated in early EECs. ABCB11, LOC647065 and cDNA FLJ12258 fis are down in tumors, especially in late EECs, while LMO4 particularly down in early EECs.

![**A six-gene signature dividing early and late EECs**. (**A**) Further narrowing down the existing gene signature to fewer genes. When probe sets were ranked by their signal-to-noise ratios (weights), the top 6 features form the smallest panel which can give the best classification effect. (**B**) A prediction strength (PS) plot shows the prediction strength of these 6 genes. They give the same classification effect as that of the 217-probeset signature. (**C**) Signature evaluation by a testing data set. A lowest error rate (*upper*) and best classification effect (shown by a PS plot; *lower panel*) was achieved.](1471-2164-10-613-4){#F4}

###### 

Gene annotations of the six-gene signature.

  Probe Set ID   UniGene ID   Gene Title                                       Gene Symbol   Chromosomal Location
  -------------- ------------ ------------------------------------------------ ------------- ----------------------
  233113_at      Hs.633901    Homo sapiens, clone IMAGE:5759975, mRNA          \-\--         \-\--
  211224_s\_at   Hs.158316    ATP-binding cassette, B (MDR/TAP), 11            ABCB11        chr2q24
  225054_x\_at   Hs.293560    Archaemetzincins-2                               AMZ2          chr17q24.2
  209870_s\_at   Hs.525718    amyloid beta (A4) precursor protein-binding A2   APBA2         chr15q11-q12
  209205_s\_at   Hs.436792    LIM domain only 4                                LMO4          chr1p22.3
  239819_at      Hs.624027    Hypothetical protein LOC647065                   LOC647065     chr2q23.1

Re-activation of epithelial stem cell genes in advanced EECs
------------------------------------------------------------

Since our main goal is to identify EpiSC genes in EECs, we compared the gene expression profiles of EEC tissues of all 4 stages to that of normal CD133+ EpiSCs \[[@B39]\]. When the 217 genes distinguishing early and late EECs were applied to compare the relationships between EECs and EpiSCs, clearly EpiSCs have a closest relationship to late EECs (Figure [5A](#F5){ref-type="fig"}). This impression is strengthened by calculating the average linkage distances between sample groups. Compared with early EECs, EEC of both Stages III and IV are closer to EpiSCs to a similar extent (Figure [5B](#F5){ref-type="fig"}), suggesting the re-expression of EpiSC features in late EECs. A total of 26 EpiSC genes are overexpressed in advanced EECs (Figure [5C](#F5){ref-type="fig"}). Also, genes down-regulated in late EECs (the 77 probe sets in Figure [2](#F2){ref-type="fig"}) are absence in EpiSCs (Figure [5D](#F5){ref-type="fig"}). Most early EECs clustered together and expressed the intermediate level of EpiSC genes (Figure [5C-D](#F5){ref-type="fig"}), consistent with the distances analysis result in Figure [5B](#F5){ref-type="fig"}.

![**Expression of EpiSC gene patterns in EECs, especially late ones**. (**A**) Relationships between normal endometrium, EECs of different stages in the training data set and epithelial stem cells (EpiSCs). This MDS plot was drawn by the 217 features differentiating early and late EECs. (**B**) Average linkage distances between tissues and EpiSCs. The same 217 probe sets were used. The confidence limits shown represent the standard error. (**C**) A heat map shows genes overexpressed in both EpiSCs and late EECs. Gene symbols of these genes are shown. Genes associate with tumor malignancy or stem cell biology are underlined. (**D**) A heat map shows the distribution patterns of the 77 probe sets down-regulated in late EECs. These genes are also absence in EpiSCs.](1471-2164-10-613-5){#F5}

Discussion
==========

EEC still ranks one of the most fatal female cancers worldwide and disease progression very often accompany with worse clinical outcomes and treatment failure. Identifying genes or canonical pathways associated with advanced cancer can help to unmask the mechanisms of tumor malignancy as well as provide us with novel drug targets. It has been recognized clinically that cancer cells, especially the advanced and metastatic ones, possess characters reminiscent of those of normal stem cells. The degree of stem cell gene expression correlates with pivotal tumor features and patient prognosis \[[@B10],[@B11],[@B13]\]. Hence, identifying shared genes between late EECs and stem cells will provide new insights into cancer biology, as well as new prognosis markers and therapeutic targets. In this study, we identified a 217-probeset signature which could distinguish late (stages III-IV) from early (stages I-II) EECs (Figure [1](#F1){ref-type="fig"}). More low stage disease array data than high stage ones were obtained, which may partly due to the fact that the early diagnosis takes place in almost 90% of EEC clinically. We combined primary and metastatic late EEC samples in one group since their molecular profiles are indistinguishable (not shown). Prostate EpiSCs were used as a comparative group since array data for endometrial stem cells is not available yet. Nevertheless, prostate CD133+ cells are still epithelial stem cells and therefore good controls. Other EpiSC data should reproduce part of our findings.

Our results reveal a previously unaware link between genes associated with EpiSC identity and the histopathological traits of EECs. It is possible that these genes contribute to the stem cell-like phenotypes of late EECs. A total of 26 EpiSC genes were found overexpressed in late EECs (Figure [5C](#F5){ref-type="fig"}), and genes down-regulated in late EECs (Figure [2](#F2){ref-type="fig"}; 77 probe sets) are also absence in EpiSCs (Figure [5D](#F5){ref-type="fig"}). Among those 26 overexpressed genes there are famous oncogenes or stemness genes (Figure [5C](#F5){ref-type="fig"}, underlined). ADAM17 (A Disintegrin and A Metalloproteinase 17), also known as tumor necrosis factor-alpha converting enzyme (TACE) or less commonly CD156q, is a therapeutic target in multiple diseases since major contemporary pathologies like cancer, inflammatory and vascular diseases seem to be connected to its cleavage abilities \[[@B40]\]. CAP1 (adenylate cyclase-associated protein 1) overexpressed in pancreatic cancers is involved in cancer cell motility \[[@B41]\]. CAPG (capping protein (actin filament), gelsolin-like) also contributes in the motility of pancreatic cancer cells \[[@B42]\]. PDCD10 (CCM3) is involved in cerebral cavernous malformations (CCM) \[[@B43]\] and is found to interact with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway \[[@B44]\]. PSEN1 (presenilin 1) is involved in apoptosis, overexpressed in high-risk patients with stage I non-small cell lung cancer (NSCLC), and is in a prognosis signature of NSCLC patients \[[@B45]\]. SENP2 (SUMO-specific protease 2) is highly expressed in trophoblast cells that are required for placentation, and targeted disruption of SENP2 in mice reveals its essential role in development of all three trophoblast layers via modulating the Mdm2-p53 pathway \[[@B46]\]. The appearance of these known oncogenes or stemness genes in our data supports the reliability of our gene lists. The roles of EpiSC genes in both epithelial stem cell biology and EEC malignancy will be addressed further.

Several genes were previous suggested to be tumor suppressors. CSTA (cystatin A, or stefin A), a cysteine proteinases inhibitor, is implicated in preventing local and metastatic tumor spread of cancers. The risk of disease recurrence and disease-related death was thus higher in patients with low CSTA in patients with squamous cell carcinoma of the head and neck \[[@B30]\]. NPAS2 (neuronal PAS domain protein 2) is a circadian gene as well as a putative tumor suppressor involved in DNA damage response \[[@B47]\]. PHC3 (polyhomeotic homolog 3), a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors \[[@B48]\]. Validating their expression in different stages of EECs by further immunohistochemstry study will not only provide novel malignancy mechanisms but will also present new drug targets.

In the past few years, much effort has been put to explore the mechanisms and additional molecular markers for predicting prognosis of EECs by using high-throughput genomics technology. Gene expression microarray (GEM) is a popular platform among all of those high-throughput genomics techniques. In this study we applied GEM and machine learning algorithms to filtrate out a 217-probeset signature for disease diagnosis. Many of the filtrated genes have been linked to tumor progression and malignancy, supporting the reliability of our array data. Moreover, we narrowed down this 217-probeset profile to a six-gene mini-signature for the differentiation of early to late EECs in the training set. This signature can be validated by an independent testing cohort (Figure [4](#F4){ref-type="fig"}). Owing to the small gene number of this signature, it is now possible to check their mRNA levels in patient tissues by real-time PCR in regular clinical labs. Recently a five-gene profile and a five-microRNA signature are identified for the prediction of clinical outcomes in non-small-cell lung cancer \[[@B49],[@B50]\]. Whether our six-gene signature can be correlated with relapse-free and overall survival among patients with EEC is unclear and awaited to be elucidated. Also, whether the protein expression levels of these 6 genes correlate with those of mRNAs is unclear. Since most of the patients in either training or testing data set were Caucasian (Table [1](#T1){ref-type="table"}), whether this gene signature can be applied in patients with various genetic backgrounds should also be studied.

In our datasets we noticed that few early EEC cases expressed already late EEC genes and therefore could not be classified correctly (Figs. [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). Since patients with late and metastatic EEC tend to have poor prognosis, whether these unusual early cases possess worse clinical outcomes is an interesting issue. It has been suggested that prognosis potential of human tumors is inherited in early lesions. For example, the gene expression patterns in metastatic colorectal carcinoma are readily distinguishable from those associated with *in situ*tumors \[[@B24],[@B51]\]. A subset of primary tumors resembled metastatic tumors with respect to this gene-expression signature \[[@B24],[@B51]\]. Very recently Varmus and colleagues showed that when untransformed mouse mammary cells were introduced into the systemic circulation of a mouse, those cells can bypass transformation at the primary site, form long-term residence in the lungs but do not form ectopic tumors \[[@B52]\]. Husemann et al. also observed that systemic spread can be an early step in breast cancer. Tumor cells can disseminate systemically from earliest epithelial alterations and form and micrometastasis in bone marrow and lungs \[[@B53]\]. Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis. The metastatic potential of human tumors is encoded in the bulk of a primary tumor and, at least in a subset of patients, metastatic capability in cancers is an inherent feature. Our EEC gene signatures therefore hold the potential of being a novel prognosis panel. More advanced therapy and clinical follow-up should be applied on early stage patients with molecular feature similar to that of EpiSC.

In advanced EECs, tumor tissues express more genes abundant in CD133+ EpiSC and acquired a stem cell trait (Figure [5](#F5){ref-type="fig"}). The expression of these EpiSC genes in late EECs may due to the re-expression of EpiSC features in late stage EECs, i.e., further mutations and stem cell gene reactivation in certain early EECs. The intermediate EpiSC gene expression level in early EECs supports this point (Figure [5A](#F5){ref-type="fig"} &[5C-D](#F5){ref-type="fig"}). Recent studies demonstrated that EMT contributes to the acquisition of stem cell traits in cancer cells and the induction of EMT inducer Snail results in stemness gene expression \[[@B14],[@B15]\]. Whether EMT also contributes in EEC progression and metastasis is an interesting issue to follow. However, we did not rule out the possibility that certain late EECs may arise from an independent rapidly progressing cancer utilizing stemness molecular pathways. According to the tumor stem cell theory, cancer cells may be originated from different cancer stem cells acquiring distinctive oncogenic mutations. Certain early EECs have the capacity to progress to late stage disease may due to a mechanism that they arose from the same mutated progenitor cells as late EECs. The observation that several early EEC cases express EpiSC genes already (Figure [1D](#F1){ref-type="fig"} &[5C](#F5){ref-type="fig"}) favors the later hypotheses. These 2 situations may both exist *in vivo*, but our profiling work cannot favor any of them yet. Nevertheless, genes filtrated here will provide clinicians novel prognosis markers and therapeutic targets.

Conclusions
===========

In summary, here we reveal distinct epithelial stem cell traits and gene expression patterns in late EECs and some of these genes hold the potential of being novel drug targets. Drugs targeting MAP kinase pathway, for example, may be applied for the treatment of late EEC since this canonical pathway is significantly up in late EECs (Table [5](#T5){ref-type="table"}). Since applying a statistical analysis of gene ontology terms is the reliance on prior knowledge of the biological activity of each differentially expressed gene, the enrichment of genes associated with specific pathways may be a consequence of intense research in such areas. Hence, new canonical pathways may still exist and may serve as candidate therapeutic targets. Function of the filtrated KIAA (such as KIAA0323, Figure [5C](#F5){ref-type="fig"}) and LOC series of anonymous ESTs (such as C20orf24, Figure [5C](#F5){ref-type="fig"}) in Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}, [7](#T7){ref-type="table"} should be studied and their roles in tumor malignancy, chemoresistance and EpiSC stemness are awaited to be elucidated. Further studies to prove the prognosis values and therapeutic potentials of the identified genes, especially those also present in epithelial stem cells, should lead to a better understanding of EEC and EpiSC biology and the susceptibilities of late EECs to treatment.

Methods
=======

Microarray data sets
--------------------

All array data were implemented by the Affymetrix™ HG-U133 Plus 2.0 GeneChip. Array data of normal CD133+ epithelial stem cells, which were used as a normal counterpart of cancer stem cells \[[@B39]\], isolated from benign prostatic hyperplasia were downloaded from the ArrayExpress database at the European Bioinformatics Institute (<http://www.ebi.ac.uk/microarray-as/ae/>; Accession No. E-MEXP-993; array data files 1325504978.cel, 1325505459.cel and 1325505089.cel were used).

The gene expression profiles of EEC tissues of different stages were generated by the International Genomics Consortium (IGC) under the expO (Expression Project for Ontology) project and were downloaded from Gene Expression Omnibus (GEO <http://www.ncbi.nlm.nih.gov/geo/>; GSE2109). EEC array data were divided into training (n = 33; incl. all 4 stages) and testing cohorts (n = 15) (details in Table [1](#T1){ref-type="table"}). Array data of normal endometrium controls were from a Human body index dataset in GEO (GSE7307).

Array data processing
---------------------

Feature selection was performed as previously described \[[@B22]\]. Briefly, the default robust multichip average (RMA) settings were used to background correct, normalize and summarize all expression values using the \'affy\' package of the Bioconductor suite of software <http://www.bioconductor.org/> for the R statistical programming language. A t-statistic was calculated as normal for each gene and a *p*-value then calculated using a modified permutation test in the \"LIMMA\" package \[[@B22]\]. To control the multiple testing errors, a false discovery rate (FDR) algorithm was then applied to these *p*-values to calculate a set of *q*-values: thresholds of the expected proportion of false positives, or false rejections of the null hypothesis \[[@B22],[@B54]\]. Gene annotation was performed by the ArrayFusion web tool <http://microarray.ym.edu.tw/tools/arrayfusion/>\[[@B55]\]. Gene enrichment analysis was performed by the Gene Ontology (GO) database using the DAVID Bioinformatics Resources 2008 interface <http://david.abcc.ncifcrf.gov/>, a graph theory evidence-based method to agglomerate gene or protein identifiers \[[@B56],[@B57]\].

Bioinformatics analysis
-----------------------

The discrimination power of filtrated genes was evaluated by a machine-learning approach combining the weighted voting algorithm \[[@B24]\] and leave-one-out cross-validation (LOOCV). This approach has been integrated in our Java tool <http://microarray.ym.edu.tw/tools/set/>\[[@B25]\]. In brief, the uploaded genes are ranked according to the absolute values of corresponding signal-to-noise scores \[[@B24]\] in a descending order. Genes are included into a signature one at a time based on the order of ranking. The error rate for each new signature is estimated by the weighted voting algorithm and LOOCV and can be monitored by an error rate distribution plot \[[@B25]\]. Based on the error rate information, we then selected an appropriate composition of discriminating genes with the lowest error rate. Once a signature is defined, the result of prediction strength (PS) analysis for each sample was shown. The PS values range from -1 to +1, where higher absolute values reflect stronger predictions \[[@B25]\]. An overview of the results for samples in different groups was then illustrated by a PS plot \[[@B25]\].

Classical multidimensional scaling (MDS) is performed by the standard function of the R program to provide a visual impression of how the various sample groups are related. The average linkage distance between samples is calculated by the Pearson correlation subtracted from unity to provide bounded distances in the range (0, 2), as described in our previous study \[[@B22]\]. The distance between two groups of samples is calculated using the average linkage measure (the mean of all pair-wise distances (linkages) between members of the two groups concerned). The standard error of the average linkage distance between two groups (the standard deviation of pair-wise linkages divided by the square root of the number of linkages) is quoted when inter-group distances are compared in the text.

Immunohistochemical staining
----------------------------

Staining was performed on formalin-fixed, paraffin-embedded specimens using anti-ERBB2 primary antibody (DAKO, Carpinteria, CA, USA). Scoring was performed as following. 0: undetectable staining or membrane staining in \<10% of the tumor cells. 1+: faint and incomplete membrane staining in \>10% of the tumor cells; 2+: weak to moderate complete membrane staining in \>10% of the tumor cells; 3+: strong complete membrane staining observed in \>10% of the tumor cells. ERBB2 protein expression was categorized as negative (scores 0 and 1+), or positive (scores 2+ and 3+) \[[@B29]\].
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